Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$41.87 USD
-0.74 (-1.74%)
Updated May 17, 2024 04:00 PM ET
After-Market: $41.91 +0.04 (0.10%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RARE 41.87 -0.74(-1.74%)
Will RARE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RARE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RARE
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say
RARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
Repligen (RGEN) Misses Q1 Earnings Estimates
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
Other News for RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Truist Financial
Wall Street Analysts Are Bullish on Top Healthcare Picks
Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Ionis Pharmaceuticals (IONS)
Ultragenyx Pharmaceutical: A Leading Contender in Angelman Syndrome Therapy with a Strong Buy Rating